Institution
Université catholique de Louvain
Education•Louvain-la-Neuve, Belgium•
About: Université catholique de Louvain is a education organization based out in Louvain-la-Neuve, Belgium. It is known for research contribution in the topics: Population & Catalysis. The organization has 25319 authors who have published 57360 publications receiving 2172080 citations. The organization is also known as: University of Louvain & UCLouvain.
Papers published on a yearly basis
Papers
More filters
••
Centre national de la recherche scientifique1, Foundation for Research & Technology – Hellas2, Université libre de Bruxelles3, University of Salamanca4, Autonomous University of Madrid5, University of Paris6, Instituto Gulbenkian de Ciência7, Goethe University Frankfurt8, Ludwig Maximilian University of Munich9, University of Manchester10, Pasteur Institute11, Université catholique de Louvain12, Royal Children's Hospital13, French Institute of Health and Medical Research14, John Radcliffe Hospital15, VU University Amsterdam16, University of Konstanz17, Carlsberg Laboratory18, University of Wrocław19
TL;DR: The complete DNA sequence of the yeast Saccharomyces cerevisiae chromosome XI has been determined, and the 666,448-base-pair sequence has revealed general chromosome patterns.
Abstract: The complete DNA sequence of the yeast Saccharomyces cerevisiae chromosome XI has been determined. In addition to a compact arrangement of potential protein coding sequences, the 666,448-base-pair sequence has revealed general chromosome patterns; in particular, alternating regional variations in average base composition correlate with variations in local gene density along the chromosome. Significant discrepancies with the previously published genetic map demonstrate the need for using independent physical mapping criteria.
383 citations
••
TL;DR: The modulation of gut barrier function through nutritional interventions, including strategies to manipulate the microbiota, is considered a relevant target for novel therapeutic and preventive treatments against a range of diseases.
Abstract: The gut barrier plays a crucial role by spatially compartmentalizing bacteria to the lumen through the production of secreted mucus and is fortified by the production of secretory IgA (sIgA) and antimicrobial peptides and proteins. With the exception of sIgA, expression of these protective barrier factors is largely controlled by innate immune recognition of microbial molecular ligands. Several specialized adaptations and checkpoints are operating in the mucosa to scale the immune response according to the threat and prevent overreaction to the trillions of symbionts inhabiting the human intestine. A healthy microbiota plays a key role influencing epithelial barrier functions through the production of short-chain fatty acids (SCFAs) and interactions with innate pattern recognition receptors in the mucosa, driving the steady-state expression of mucus and antimicrobial factors. However, perturbation of gut barrier homeostasis can lead to increased inflammatory signaling, increased epithelial permeability, and dysbiosis of the microbiota, which are recognized to play a role in the pathophysiology of a variety of gastrointestinal disorders. Additionally, gut-brain signaling may be affected by prolonged mucosal immune activation, leading to increased afferent sensory signaling and abdominal symptoms. In turn, neuronal mechanisms can affect the intestinal barrier partly by activation of the hypothalamus-pituitary-adrenal axis and both mast cell-dependent and mast cell-independent mechanisms. The modulation of gut barrier function through nutritional interventions, including strategies to manipulate the microbiota, is considered a relevant target for novel therapeutic and preventive treatments against a range of diseases. Several biomarkers have been used to measure gut permeability and loss of barrier integrity in intestinal diseases, but there remains a need to explore their use in assessing the effect of nutritional factors on gut barrier function. Future studies should aim to establish normal ranges of available biomarkers and their predictive value for gut health in human cohorts.
382 citations
••
TL;DR: Sensation of leukemic cells with growth factors is a clinically applicable means of enhancing the efficacy of chemotherapy in patients with AML and does not improve the outcome in the subgroup with an unfavorable prognosis.
Abstract: BACKGROUND: Sensitization of leukemic cells with hematopoietic growth factors may enhance the cytotoxicity of chemotherapy in acute myeloid leukemia (AML). METHODS: In a multicenter randomized trial, we assigned patients (age range, 18 to 60 years) with newly diagnosed AML to receive cytarabine plus idarubicin (cycle 1) and cytarabine plus amsacrin (cycle 2) with granulocyte colony-stimulating factor (G-CSF) (321 patients) or without G-CSF (319). G-CSF was given concurrently with chemotherapy only. Idarubicin and amsacrin were given at the end of a cycle to allow the cell-cycle-dependent cytotoxicity of cytarabine in the context of G-CSF to have a greater effect. The effect of G-CSF on disease-free survival was assessed in all patients and in cytogenetically distinct prognostic subgroups. RESULTS: After induction chemotherapy, the rates of response were not significantly different in the two groups. After a median follow-up of 55 months, patients in complete remission after induction chemotherapy plus G-CSF had a higher rate of disease-free survival than patients who did not receive G-CSF (42 percent vs. 33 percent at four years, P=0.02), owing to a reduced probability of relapse (relative risk, 0.77; 95 percent confidence interval, 0.61 to 0.99; P=0.04). G-CSF did not significantly improve overall survival (P=0.16). Although G-CSF did not improve the outcome in the subgroup with an unfavorable prognosis, the 72 percent of patients with standard-risk AML benefited from G-CSF therapy (overall survival at four years, 45 percent, as compared with 35 percent in the group that did not receive G-CSF [relative risk of death, 0.75; 95 percent confidence interval, 0.59 to 0.95; P=0.02]; disease-free survival, 45 percent vs. 33 percent [relative risk, 0.70]; 95 percent confidence interval, 0.55 to 0.90; P=0.006). CONCLUSIONS: Sensitization of leukemic cells with growth factors is a clinically applicable means of enhancing the efficacy of chemotherapy in patients with AML.
381 citations
••
TL;DR: This study is the first to characterise gut microbiome in patients with HCC and to report the successful diagnosis model establishment and cross-region validation of microbial markers for HCC.
Abstract: Objective To characterise gut microbiome in patients with hepatocellular carcinoma (HCC) and evaluate the potential of microbiome as non-invasive biomarkers for HCC Design We collected 486 faecal samples from East China, Central China and Northwest China prospectively and finally 419 samples completed Miseq sequencing We characterised gut microbiome, identified microbial markers and constructed HCC classifier in 75 early HCC, 40 cirrhosis and 75 healthy controls We validated the results in 56 controls, 30 early HCC and 45 advanced HCC We further verified diagnosis potential in 18 HCC from Xinjiang and 80 HCC from Zhengzhou Results Faecal microbial diversity was increased from cirrhosis to early HCC with cirrhosis Phylum Actinobacteria was increased in early HCC versus cirrhosis Correspondingly, 13 genera including Gemmiger and Parabacteroides were enriched in early HCC versus cirrhosis Butyrate-producing genera were decreased, while genera producing-lipopolysaccharide were increased in early HCC versus controls The optimal 30 microbial markers were identified through a fivefold cross-validation on a random forest model and achieved an area under the curve of 8064% between 75 early HCC and 105 non-HCC samples Notably, gut microbial markers validated strong diagnosis potential for early HCC and even advanced HCC Importantly, microbial markers successfully achieved a cross-region validation of HCC from Northwest China and Central China Conclusions This study is the first to characterise gut microbiome in patients with HCC and to report the successful diagnosis model establishment and cross-region validation of microbial markers for HCC Gut microbiota-targeted biomarkers represent potential non-invasive tools for early diagnosis of HCC
381 citations
••
TL;DR: Among the ORFs with a high degree of similarity to known sequences are a collection of putative transposases, resolvases, and integrases, suggesting an evolution involving lateral movement of DNA among species.
Abstract: The Bacillus anthracis Sterne plasmid pXO1 was sequenced by random, "shotgun" cloning. A circular sequence of 181,654 bp was generated. One hundred forty-three open reading frames (ORFs) were predicted using GeneMark and GeneMark.hmm, comprising only 61% (110,817 bp) of the pXO1 DNA sequence. The overall guanine-plus-cytosine content of the plasmid is 32.5%. The most recognizable feature of the plasmid is a "pathogenicity island," defined by a 44.8-kb region that is bordered by inverted IS1627 elements at each end. This region contains the three toxin genes (cya, lef, and pagA), regulatory elements controlling the toxin genes, three germination response genes, and 19 additional ORFs. Nearly 70% of the ORFs on pXO1 do not have significant similarity to sequences available in open databases. Absent from the pXO1 sequence are homologs to genes that are typically required to drive theta replication and to maintain stability of large plasmids in Bacillus spp. Among the ORFs with a high degree of similarity to known sequences are a collection of putative transposases, resolvases, and integrases, suggesting an evolution involving lateral movement of DNA among species. Among the remaining ORFs, there are three sequences that may encode enzymes responsible for the synthesis of a polysaccharide capsule usually associated with serotype-specific virulent streptococci.
381 citations
Authors
Showing all 25540 results
Name | H-index | Papers | Citations |
---|---|---|---|
Robert Langer | 281 | 2324 | 326306 |
Pulickel M. Ajayan | 176 | 1223 | 136241 |
Klaus Müllen | 164 | 2125 | 140748 |
Giacomo Bruno | 158 | 1687 | 124368 |
Willem M. de Vos | 148 | 670 | 88146 |
David Goldstein | 141 | 1301 | 101955 |
Krzysztof Piotrzkowski | 141 | 1269 | 99607 |
Andrea Giammanco | 135 | 1362 | 98093 |
Christophe Delaere | 135 | 1320 | 96742 |
Vincent Lemaitre | 134 | 1310 | 99190 |
Michael Tytgat | 134 | 1449 | 94133 |
Jian Li | 133 | 2863 | 87131 |
Jost B. Jonas | 132 | 1158 | 166510 |
George Stephans | 132 | 1337 | 86865 |
Peter Hall | 132 | 1640 | 85019 |